JP7042836B2 - 癌を処置する方法 - Google Patents

癌を処置する方法 Download PDF

Info

Publication number
JP7042836B2
JP7042836B2 JP2019548368A JP2019548368A JP7042836B2 JP 7042836 B2 JP7042836 B2 JP 7042836B2 JP 2019548368 A JP2019548368 A JP 2019548368A JP 2019548368 A JP2019548368 A JP 2019548368A JP 7042836 B2 JP7042836 B2 JP 7042836B2
Authority
JP
Japan
Prior art keywords
compound
cancer
fxr
cca
mice
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019548368A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020510009A (ja
JP2020510009A5 (https=
Inventor
アントニオ モシェッタ，
ヘスス マリア バニャレス アスルメディ，
ルイス ブハンダ フェルナンデス デ ピエロラ，
マリア ヘスス ペルゴリア モンティエル，
オイアネ エリセ アスパレン，
Original Assignee
インターセプト ファーマシューティカルズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by インターセプト ファーマシューティカルズ， インコーポレイテッド filed Critical インターセプト ファーマシューティカルズ， インコーポレイテッド
Publication of JP2020510009A publication Critical patent/JP2020510009A/ja
Publication of JP2020510009A5 publication Critical patent/JP2020510009A5/ja
Application granted granted Critical
Publication of JP7042836B2 publication Critical patent/JP7042836B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2019548368A 2017-03-07 2017-09-21 癌を処置する方法 Active JP7042836B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762468259P 2017-03-07 2017-03-07
US62/468,259 2017-03-07
PCT/US2017/052663 WO2018164715A1 (en) 2017-03-07 2017-09-21 Methods of treating cancer

Publications (3)

Publication Number Publication Date
JP2020510009A JP2020510009A (ja) 2020-04-02
JP2020510009A5 JP2020510009A5 (https=) 2020-10-15
JP7042836B2 true JP7042836B2 (ja) 2022-03-28

Family

ID=63447943

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019548368A Active JP7042836B2 (ja) 2017-03-07 2017-09-21 癌を処置する方法

Country Status (9)

Country Link
EP (1) EP3592357A4 (https=)
JP (1) JP7042836B2 (https=)
KR (1) KR20190122251A (https=)
CN (1) CN110430882A (https=)
AU (1) AU2017402623A1 (https=)
CA (1) CA3055308A1 (https=)
IL (1) IL269123A (https=)
TW (1) TW201832768A (https=)
WO (1) WO2018164715A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022011037A2 (en) * 2020-07-07 2022-01-13 The General Hospital Corporation Interleukin 33 (il-33) inhibition for treatment of cancer, fibrosis and inflammation
WO2023043375A2 (en) * 2021-09-16 2023-03-23 Agency For Science, Technology And Research Modulation of tjp1 expression to treat liver diseases

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010500285A (ja) 2006-06-27 2010-01-07 インターセプト ファーマシューティカルズ， インコーポレイテッド Ｆｘｒ媒介疾患または状態の予防または治療のためのｆｘｒリガンドとしての胆汁酸誘導体
WO2013037482A1 (en) 2011-09-15 2013-03-21 Phenex Pharmaceuticals Ag Farnesoid x receptor agonists for cancer treatment and prevention
JP2016500111A (ja) 2012-11-28 2016-01-07 インターセプト ファーマシューティカルズ， インコーポレイテッド 肺疾患の処置
WO2016176208A1 (en) 2015-04-27 2016-11-03 Intercept Pharmaceuticals, Inc. Compositions of obeticholic acid and methods of use
WO2017180577A1 (en) 2016-04-13 2017-10-19 Intercept Pharmaceuticals, Inc. Methods of treating cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050107475A1 (en) * 2002-03-21 2005-05-19 Jones Stacey A. Methods of using farnesoid x receptor (frx) agonists
US10166246B2 (en) * 2014-05-27 2019-01-01 City Of Hope TGR5 agonist complexes for treating diabetes and cancer
US11578097B2 (en) * 2014-11-26 2023-02-14 Enanta Pharmaceuticals, Inc. Tetrazole derivatives of bile acids as FXR/TGR5 agonists and methods of use thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010500285A (ja) 2006-06-27 2010-01-07 インターセプト ファーマシューティカルズ， インコーポレイテッド Ｆｘｒ媒介疾患または状態の予防または治療のためのｆｘｒリガンドとしての胆汁酸誘導体
WO2013037482A1 (en) 2011-09-15 2013-03-21 Phenex Pharmaceuticals Ag Farnesoid x receptor agonists for cancer treatment and prevention
JP2016500111A (ja) 2012-11-28 2016-01-07 インターセプト ファーマシューティカルズ， インコーポレイテッド 肺疾患の処置
WO2016176208A1 (en) 2015-04-27 2016-11-03 Intercept Pharmaceuticals, Inc. Compositions of obeticholic acid and methods of use
WO2017180577A1 (en) 2016-04-13 2017-10-19 Intercept Pharmaceuticals, Inc. Methods of treating cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Hepatology，2016年，Vol.65，pp.920-928

Also Published As

Publication number Publication date
WO2018164715A1 (en) 2018-09-13
KR20190122251A (ko) 2019-10-29
TW201832768A (zh) 2018-09-16
EP3592357A1 (en) 2020-01-15
CN110430882A (zh) 2019-11-08
JP2020510009A (ja) 2020-04-02
AU2017402623A1 (en) 2019-09-26
EP3592357A4 (en) 2021-01-13
CA3055308A1 (en) 2018-09-13
IL269123A (en) 2019-11-28

Similar Documents

Publication Publication Date Title
JP6968821B2 (ja) 癌を治療する方法
KR102471590B1 (ko) Hdac 억제제 및 pd-l1 억제제의 병용 요법
JP2019519498A5 (https=)
TW202216161A (zh) 氧合膽固醇硫酸酯於治療與人類疱疹病毒第四型（ｅｂ病毒）相關之癌和非癌的轉化之用途
WO2006113493A2 (en) Methods of determining cancer prognosis via natural killer cell activity
JP7042836B2 (ja) 癌を処置する方法
EP3411058B1 (en) Combination therapy with a6 and paclitaxel for the treatment of ovarian cancer
JP3236297U (ja) 臨床現場薬物送達装置および方法
JP3231487U (ja) 薬剤直接輸液装置
US20180256600A1 (en) Methods of treating cancer
CN113271951A (zh) 使用奥贝胆酸的方法
HK40010220A (en) Methods of treating cancer
HK1260434A1 (en) Methods of treating cancer
US20230272103A1 (en) Cd44-modulating compositions for methods for treating cancers and ascites
HK40129132A (zh) Hdac抑制剂和pd-1抑制剂的组合疗法
CA2925305A1 (en) Combination therapy with a6 and chemotherapeutic agents for the treatment of cancer
EA042997B1 (ru) Комбинированная терапия рака ингибитором hdac и ингибитором pd-l1
HK40001457A (en) Combination therapy with a6 and paclitaxel for the treatment of ovarian cancer
HK40001457B (en) Combination therapy with a6 and paclitaxel for the treatment of ovarian cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200907

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200907

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210630

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210719

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211019

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220228

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220315

R150 Certificate of patent or registration of utility model

Ref document number: 7042836

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250